Relevant bibliographies by topics / Zhi yao ye

Academic literature on the topic 'Zhi yao ye'

Author: Grafiati
Published: 26 July 2024
Last updated: 27 July 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Zhi yao ye.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Zhi yao ye"

1

Long, Haiping, and Pengfei Kuang. "Modern Chinese confirmative shi." Functions of Language 24, no. 3 (December 31, 2017): 294–318. http://dx.doi.org/10.1075/fol.15018.lon.

Full text
Abstract:
Abstract Modern Chinese confirmative shi (as in mei cuo, wo shi yao dusi ni (沒錯，我是要毒死你) ‘that’s right. I really wanted to poison you to death’) is not an auxiliary but an adverb. It derives from the adjective shi ‘true, real’ in Old Chinese (Yan zhi yan shi ye (偃之言是也) ‘what Yan said was true’). The grammaticalization pathway of the Modern Chinese confirmative shi is different from that of the copula shi (Laozhang shi huoche siji (老張是貨車司機) ‘Laozhang is a truck driver’) or the auxiliary shi (Laozhang shi kai huoche, wo shi kai keche (老張是開貨車，我是開客車) ‘Laozhang drives a truck and I drive a coach car’). Modern Chinese confirmative shi, copula shi, and auxiliary shi have the same morphological form because they all appear to derive from the adjective shi or demonstrative ( shi ke ren, shu bu ke ren ( 是可忍，孰不可忍) ‘if this could be endured, is there anything else that could not be endured’) in Old Chinese. Such a pattern of morphological sameness seems to be cross-linguistically rare, if not unique.
APA, Harvard, Vancouver, ISO, and other styles
2

Lei, Jiafeng, and Yi-Chun Lu. "High Areal-Capacity Aqueous Manganese-Based Batteries Enabled by Redox Mediators." ECS Meeting Abstracts MA2023-01, no. 3 (August 28, 2023): 744. http://dx.doi.org/10.1149/ma2023-013744mtgabs.

Full text
Abstract:
Aqueous manganese batteries based on deposition-dissolution of Mn2+/MnO2 reactions have aroused great attention due to their intrinsic low cost, high potential, and high energy.1, 2 However, the incomplete dissolution and exfoliated dead MnO2 would inevitably lead to capacity loss and poor cyclability at high areal capacity application.3, 4 Herein, we apply a redox mediator strategy to dissolve the accumulated MnO2 via a spontaneous chemical reaction between redox mediators iodide and MnO2.5,6 During the discharge process, the iodide (I–) could react with the residual MnO2 and be oxidized to I3 – that could be further reduced back to I– on the electrode, continuing this process until fully dissolved the accumulated MnO2. We will discuss detailed reaction mechanisms verified by ex-situ UV-vis spectroscopy, scanning electron microscopy, and X-ray diffraction. The zinc-manganese (Zn-Mn) battery with iodide mediator showed improved cycling stability at 2.5 mAh cm–2 (400 vs. 100 cycles, static mode) and 15 mAh cm–2 (225 vs. 60 cycles, flow mode). Areal capacity is one of the most important parameters determining system energy for deposition-based batteries.7 The Zn-Mn flow cell could demonstrate a high areal capacity application at 50 mAh cm–2 for 50 cycles. We will discuss how to expand this strategy to other manganese-based batteries and broaden the horizon of aqueous batteries. Acknowledgment This work is supported by a grant from the Research Grant Council of the Hong Kong Special Administrative Region, China (project no. C1002-21G). Reference W. Chen, G. Li, A. Pei, Y. Li, L. Liao, H. Wang, J. Wan, Z. Liang, G. Chen, H. Zhang, J. Wang and Y. Cui, Nat. Energy, 2018, 3, 428-435. D. Chao, W. Zhou, C. Ye, Q. Zhang, Y. Chen, L. Gu, K. Davey and S.-Z. Qiao, Angew. Chem. Int. Ed. Engl., 2019, 58, 7823-7828. C. Liu, X. Chi, Q. Han and Y. Liu, Adv. Energy Mater., 2020, 10, 1903589. G. Liang, F. Mo, H. Li, Z. Tang, Z. Liu, D. Wang, Q. Yang, L. Ma and C. Zhi, Adv. Energy Mater., 2019, 9, 1901838. J. Lei, Y. Yao, Z. Wang and Y.-C. Lu, Energy Environ. Sci., 2021, 14, 4418-4426. J. Lei, Y. Yao, Y. Huang and Y.-C. Lu, ACS Energy Letters, 2022, DOI: 10.1021/acsenergylett.2c02524, 429-435. Y. Yao, J. Lei, Y. Shi, F. Ai and Y.-C. Lu, Nat. Energy, 2021, 6 (6), 582–588.
APA, Harvard, Vancouver, ISO, and other styles
3

Xia, Qi-Dong, Yao-Bing Chen, Jian-Xuan Sun, Chen-Qian Liu, Jin-Zhou Xu, Zhi-Peng Yao, Ye An, et al. "Abstract 2127: TERT C228T and KDM6A alterations are potential predictive biomarkers in non-muscle-invasive bladder cancer treated with intravesical Bacillus Calmette-Guérin instillation." Cancer Research 83, no. 7_Supplement (April 4, 2023): 2127. http://dx.doi.org/10.1158/1538-7445.am2023-2127.

Full text
Abstract:
Abstract Introduction: Bacillus Calmette-Guérin (BCG) is the standard of care for high-risk non-muscle-invasive bladder cancer (NMIBC) following transurethral resection. However, patients often have heterogeneous responses. Even among those who initially respond well to BCG, 10-20% relapse. Identification of reliable biomarkers predicting the efficacy of BCG remains an unmet need. En bloc resection is a novel technique representing a substantial advancement in the surgical management of NMIBC. We sought to investigate genomic and tumor microenvironmental (TME) profiles in NMIBC and explore potential predictive markers for BCG treatment following en-block resection. Methods: A total of 40 patients with high-risk NMIBC (cTis-T1N0M0) were retrospectively enrolled who underwent en bloc resection followed by BCG instillation. Surgical samples were subjected to NGS sequencing using a 520-gene panel (Burning Rock Biotech, Guangzhou) and multiplex immunofluorescence (mIF) assay. Results: The cohort had a median age of 63 years, and 80% were male. After a median follow-up of 21.8 months, 19/40 patients relapsed with a one-year relapse-free survival (RFS) rate of 57.5%. All tumors were microsatellite stable and showed a median TMB of 7.98muts/Mb. Genomic profiling revealed a high prevalence of alterations in TERT (55%), KDM6A (32.5%), KMT2D (32.5%), FGFR3(30%), PIK3CA (30%), TP53(27.5%), KMT2C (25%), and ARID1A (20%). TME analysis showed higher proportions of M1 macrophages and CD56 dim NK cells in the tumoral compartment and more intense infiltration of CD8+ T cells, exhausted CD8+T, CD56 bright NK cells, and M2 macrophages in the stromal compartment. Multivariate analysis identified TERT C228T mutation (HR=3.28 [95%CI:1.225-8.79], p=0.0181) and alteration in KDM6A (HR=2.94 [95%CI:1.040-8.29], p=0.042) as two independent factors associated with inferior RFS. Patients with concomitant TERT C228T and KDM6A alteration had the shortest RFS (median RFS:5.83months) compared with those who were free of (median RFS: NR) or harbored either one of the two alterations (median RFS:9.13months) (p=0.0022). We also found that tumoral infiltration of CD8+T cells was positively associated with RFS (HR=0.29 [95%CI:0.097-0.885], p=0.0208). Conclusion: The study comprehensively depicted the genomic and TME profiles in NMIBC and identified potential predictive biomarkers for BCG treatment. Our findings may facilitate the stratification of patients and better guide the clinical decision-making on the management of NMIBC. Citation Format: Qi-Dong Xia, Yao-Bing Chen, Jian-Xuan Sun, Chen-Qian Liu, Jin-Zhou Xu, Zhi-Peng Yao, Ye An, Meng-Yao Xu, Si-Han Zhang, Xing-Yu Zhong, Na Zeng, Si-Yang Ma, Hao-Dong He, Heng-Long Hu, Jia Hu, Yi Lu, Lin Shao, Si-Qi Li, Zheng Liu, Shao-Gang Wang. TERT C228T and KDM6A alterations are potential predictive biomarkers in non-muscle-invasive bladder cancer treated with intravesical Bacillus Calmette-Guérin instillation [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 2127.
APA, Harvard, Vancouver, ISO, and other styles
4

Yao, Qingqing, Changding Xue, Zhibin Xu, Lingfeng You, Zhendong Xue, Yuchang Mao, Sophie Lin, et al. "Abstract 3146: HRA00130-C004, a novel anti-DLL3 ADC with bystander effect, high DAR and favorable safety profiles." Cancer Research 84, no. 6_Supplement (March 22, 2024): 3146. http://dx.doi.org/10.1158/1538-7445.am2024-3146.

Full text
Abstract:
Abstract Small Cell Lung Cancer (SCLC) is a highly aggressive neuroendocrine tumor, accounting for ~15% of all new lung cancer cases1. It is estimated that there are 250,000 new SCLC cases and at least 200,000 deaths globally each year2. SCLC exhibits high recurrence after first-line treatment, poor response to subsequent therapies, and rare survival3. Lacking of recommended treatments for prolonging survival remains a problem over decades4. DLL3 is an inhibitory ligand of the Notch receptor. It binds to its Notch receptor through a cis-interaction, thus, mediates inhibition of Notch pathway to facilitate neuroendocrine tumorigenesis5. DLL3 is highly upregulated and aberrantly expressed on the cell surface in SCLC and other high-grade neuroendocrine tumors with limited expression in normal tissues6.Here we presented a DLL3-directed ADC, HRA00130-C004, which features a differentiated topoisomerase I inhibitor payload DXh conjugated via a cleavable linker to a humanized IgG1 antibody. HRA00130-C004 strongly inhibited the proliferation of cell lines with different DLL3 expression. In the bystander killing assays, HRA00130-C004 was able to kill both DMS53 cells (DLL3 over-expressed) and U-2OS (DLL3-negative) cells when they are co-cultured. The in vivo treatment of HRA00130-C004 resulted in a dramatic and sustained inhibition of tumor growth in H1184 (DLL3 high) and DMS53 (DLL3 low) xenograft models. No obvious weight loss was observed during the experiment. Furthermore, HRA00130-C004 demonstrated a favorable PK profile and satisfactory molecular integrity in rats with 3mg/kg dosing and cynomolgus monkeys with 10 mg/kg dosing. The exposure of total antibody and intact ADC was consistent. Moreover, HRA00130-C004 was well tolerated in rats and cynomolgus monkeys with no related adverse findings, which indicated its favorable safety profiles. In summary, taking advantage of Hengrui’s DXh platform, HRA00130-C004 has demonstrated great potency and good safety profiles. These data support the future clinical development of HRA00130-C004. 1.CA Cancer J. Clin., 2018, 68, 7; 2.J. Natl. Compr. Cancer Netw. 2018, 16, 1171; 3.Mol. Ther. Oncolytics, 2021, 20, 470; 4.Journal of Cancer, 2022, 13, 2945; 5.Cellular Oncology, 2019, 42, 261; 6.Journal of Hematology and Oncology 2019, 12, 61; Citation Format: Qingqing Yao, Changding Xue, Zhibin Xu, Lingfeng You, Zhendong Xue, Yuchang Mao, Sophie Lin, Jun Feng, Zhe Zhang, Xin Ye, Min Hu, Feng He. HRA00130-C004, a novel anti-DLL3 ADC with bystander effect, high DAR and favorable safety profiles [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 3146.
APA, Harvard, Vancouver, ISO, and other styles
5

Yellu, Mahender, and Stephen Medlin. "Secondary Hemophagocytic Lymphohistiocytosis As a Presentation For Peripheral T-Cell Lymphoma." Blood 122, no. 21 (November 15, 2013): 5068. http://dx.doi.org/10.1182/blood.v122.21.5068.5068.

Full text
Abstract:
Abstract Hemophagocytic lymphohistiocytosis (HLH) is often an elusive diagnosis in adults. HLH can be primary or secondary, with treatment of secondary HLH based on the cause. It is important to identify malignancy if present to help best optimize outcomes long term. HLH is characterized clinically by highly activated, ineffective immune response with cytopenia. HLH patients often present with subtle and generalized symptoms such as fever, hepatosplenomegaly, pancytopenia and lymphadenopathy. In secondary HLH, several factors serve as triggers. These are divided into infectious, malignant, rheumatologic, and during immunosuppression. Infection and malignancy are the most common causes. One study reported 28 patients with secondary HLH, 13/28 (46%) had infectious cause (11 positive EBV serology and two patients had leishmaniasis); lymphoma was identified in 11/28 (39%) and autoimmune disease in 3 (10%)1. Another study included 56 patients with secondary HLH, 43 (76%) patients had malignancy, and 23 (41%) patients had infectious etiology. Underlying immune deficiency was present in 38 (67.8%) patients2. Although primary HLH is well documented in the literature, secondary or acquired HLH is only reported in the form of cases, small retrospective studies and single institutional case series reports. Secondary HLH is highly underreported due to its rarity and nonspecific presentation. Here we present a case of secondary HLH from T-cell lymphoma; discuss clinical features and importance of initial accurate diagnosis in optimizing outcomes. A 41 y/o gentleman with past medical history of Crohn’s disease for 5 years, presented to the emergency room for fevers of approximately 2-week duration. His therapy for Crohn’s disease included, steroids, azathioprine and two doses of adalimumab. He had pancytopenia and bone marrow biopsy demonstrated hemophagocytosis. The HLH diagnosis was further supported by elevated ferritin and elevated soluble IL-2 receptor. Cytogenetics of bone marrow sample demonstrated complex karyotype. The infectious work up demonstrated Epstein Barr Virus (EBV) by PCR. Genetic testing was unremarkable. Patient was managed based on 2004-HLH protocol with dose reduction for pancytopenia. He was maintained on oral cyclosporine and stopped after 6 months when he started having fevers and pancytopenia again. Repeat bone marrow biopsy demonstrated no reactivation of HLH but noted lymphocytosis, consistent with peripheral T cell lymphoma. Cytogenetic studies demonstrated the same complex clone but now with evolution. He received CHOP chemotherapy and etoposide was added after his cerebrospinal fluid was positive for lymphoma. PET-CT showed extensive changes in the bone marrow, spleen and T1 vertebral body. Patient responded poorly and care was drawn on d28 after CHOP. Secondary HLH is an uncommon disease usually triggered by an infection, hematologic malignancy or it may occur in the setting of a rheumatologic disease. Lymphoma is common in secondary HLH and peripheral T cell lymphoma is more commonly resistant at relapse. Clonal abnormalities may help to earlier identify individuals with an underlying malignancy. Patients may benefit from thorough evaluation at presentation for underlying hematologic malignancy as management differs completely. Studies such as PET scan should be considered to search for underlying occult malignancy and cytogenetic studies need to be performed on marrow samples. In our case, repeat cytogentic studies revealed the same clone that was diagnosed at presentation. Initial appropriate therapy for Peripheral T cell lymphoma may have improved this outcome. 1. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2010 Apr;18(2):463-5. Intensive Care Med. 2010 Oct;36(10):1695-702. Disclosures: No relevant conflicts of interest to declare.
APA, Harvard, Vancouver, ISO, and other styles
6

Peng, Zhi, Hua Wang, Baorui Liu, Huiting Xu, Zhenyang Liu, Tianshu Liu, Jun Zhang, et al. "Abstract CT152: A multicenter Phase II study of savolitinib in patients with MET-amplified gastroesophogeal junction adenocarcinomas or gastric cancer." Cancer Research 83, no. 8_Supplement (April 14, 2023): CT152. http://dx.doi.org/10.1158/1538-7445.am2023-ct152.

Full text
Abstract:
Abstract Background: MET gene amplification is associated with poor prognosis in gastric cancer (GC) and gastroesophageal junction adenocarcinomas (GEJ). Savolitinib is a potent and highly selective oral MET tyrosine-kinase inhibitor. Here we reported the preliminary efficacy and safety from a phase 2 trial of savolitinib monotherapy in patients (pts) with MET-amplified advanced or metastatic GC/GEJ. (NCT04923932). Methods: Eligible pts had 2L+ GEJ or GC, with MET amplification and measurable lesions. Pts received savolitinib at 600 mg QD for body weight (BW) ≥50 kg, while 400 mg QD for BW <50 kg in 21-day cycles until disease progression or meeting other criteria for end of treatment. Savolitinib BID regimen has also been additionally explored. The primary endpoint was objective overall response rate (ORR) evaluated by Independent Review Committee (IRC). One interim analysis (IA) was pre-defined at the first 20 QD pts who had at least 2 tumor assessments. Results: As of IA, 20 pts were enrolled for QD regimen. Demographics and clinical outcomes are shown in table 1. The mean relative dose intensity of 93.07%. Median duration of exposure was 2.09 months. Confirmed ORR by IRC was 45%, and reached 50% in 16 patients with MET GCN (high) while only 1 PR was observed in 4 patients with MET GCN (low). Duration of response rate at 4-month was 85.7% with median follow up time of 5.5 months. The most common Gr≥3 TRAE (≥5%) were platelet count decreased, hypersensitivity, anemia, neutropenia and hepatic function abnormal. In all pts, only 1 patient discontinued treatment due to grade 4 liver function abnormal (TRAE) and no patient died due to TRAE. Conclusion: Savolitinib monotherapy had manageable safety and showed promising efficacy in pts with MET-amplified GEJ or GC, particularly in pts with MET high GCN. BID regimen is being investigated to further evaluate the efficacy and safety of savolitinib in pts with MET high GCN. Table 1. Pts baseline characteristics and clinical efficacy Baseline Characteristics ITT in IA (n=20) Median age (min, max), yearsSex (male/female), nECOG (0/1/2)Median BMI (min, max), (kg/m2)Primary location of tumor (GC/GEJ)Tumor stage (IV)Prior line of therapy (1/2/≥3)MET GCN (high/low) 57.00 (39.5, 76.8)17/33/15/220.8 (14.9, 25.8)16/4205/10/516/4 Clinical Efficacy By IRC By Investigator Confirmed objective response rateDisease control rate4m-DoR rate,% (95% CI) 45%65%85.7 (33.4, 97.9) 40%55%71.4 (25.8, 92.0) Citation Format: Zhi Peng, Hua Wang, Baorui Liu, Huiting Xu, Zhenyang Liu, Tianshu Liu, Jun Zhang, Yuxian Bai, Ying Yuan, Tao Wu, Feng Ye, Qinghua Pan, Jufeng Wang, Enxiao Li, Diansheng Zhong, Yueyin Pan, Yanru Qin, Yan Yang, Yusheng Wang, Aiping Zhou, Yongshun Chen, Dianbao Zhang, Hongli Liu, Xiujuan Qu, Shubin Wang, Ning Liu, Jinsheng Wu, Wei Li, Kejun Nan, Hongming Pan, Jianming Xu, Chunmei Bai, Heling Liu, Jia Wei, Runzhi Chen, Rongrong Li, Wei Li, Jinghong Zhou, Hongyan Yin, Qian Xu, Songhua Fan, Yongxin Ren, Weiguo Su, Lin Shen. A multicenter Phase II study of savolitinib in patients with MET-amplified gastroesophogeal junction adenocarcinomas or gastric cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 2 (Clinical Trials and Late-Breaking Research); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(8_Suppl):Abstract nr CT152.
APA, Harvard, Vancouver, ISO, and other styles
7

Duan, Yu-yu, Jia-yao Zhang, Mao Xie, Xiao-bo Feng, Song Xu, and Zhe-wei Ye. "Erratum to: Application of Virtual Reality Technology in Disaster Medicine." Current Medical Science, December 22, 2020. http://dx.doi.org/10.1007/s11596-020-2278-x.

Full text
Abstract:
The article “Application of Virtual Reality Technology in Disaster Medicine”, written by Yu-yu DUAN, Jia-yao ZHANG, Mao XIE, Xiao-bo FENG, Song XU, Zhe-wei YE, was originally published electronically on the publisher’s internet portal on October 2019 without open access. With the author(s)’ decision to opt for Open Choice, the copyright of the article is changed to © The Author(s) 2020 and the article is forthwith distributed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The original article has been corrected.Corresponding author: Zhe-wei YE
APA, Harvard, Vancouver, ISO, and other styles
8

Thi Ngan, Dang, Bui Thi Thanh Van, Tran Thi Ngoc Ha, Nong My Hoa, Cao Thi Phuong Thao, Nguyen Thi Hong Nhung, Duong Thi Ly Huong, Nguyen Thi Hoang Anh, Nguyen Hưu Tung, and Vu Dinh Hoang. "Saponin Composition Analysis of the Aerial Part of Panax Bipinnatifidus Seem. Collected in Sa Pa, Lao Cai." VNU Journal of Science: Medical and Pharmaceutical Sciences 35, no. 1 (June 21, 2019). http://dx.doi.org/10.25073/2588-1132/vnumps.4149.

Full text
Abstract:
Panax bipinnatifidus Seem. is a precious medicinal plant belonging to the Araliaceae family. This study qualitatively analyzed saponins of the stem, leaf and rhizome of P. bipinnatifidus by HPLC. Subsequently, by using chromatographic techniques, a major saponin from the leaf of P.bipinnatifidius Seem. was isolated. On the basis of NMR and MS spectroscopic data as well as comparison with those reported in the literature, the isolated saponin’s structure was identified as stipuleanoside R2. To the best our knowledge, this is the first report of saponin from the aerial part of P. bipinnatifidius Seem. Keywords Panax bipinnatifidus, Araliaceae, Stipuleanosid R2, HPLC.. [1] Nguyễn Văn Tập, Các loài thuộc chi Panax L. ở Việt Nam, Tạp chí Dược liệu. 10(3) (2005) 71-76. [2] Nguyễn Văn Tập, Phạm Thanh Huyền, Kết quả nghiên cứu về phân bố, sinh thái sâm vũ diệp và Tam thất hoang ở Việt Nam, Tạp chí Dược liệu. 11(5) (2006) 177-180. [3] Nguyen Huu Tung, Tran Hong Quang, Nguyen Thị Thanh Ngan, Chau Van Minh, Bui Kim Anh, Pham Quoc Long, Nguyen Manh Cuong, Young Ho Kim, Oleanolic triterpenesaponins from the roots of Panax bipinnatifidus, Chem Pharm Bull (Tokyo). 59(11) (2011) 1417-1420. [4] Đỗ Văn Hào, Nguyễn Thị Huệ, Nguyễn Thị Thu Thủy, Đặng Thị Ngần, Đào Thị Hồng Bích, Nguyễn Thị Hoàng Anh, Dương Thị Ly Hương, Nguyễn Hữu Tùng, Thành phần hóa học của phân đoạn ethyl acetat từ rễ cây sâm vũ diệp (Panax bipinnatifidus Seem.) thu hái ở Sa Pa, Lào Cai, Tạp chí Khoa học ĐHQGHN - Khoa học Y Dược. 33(2) (2017) 50-55. [5] Nguyễn Thị Thu Thủy, Nguyễn Thị Huệ, Đặng Thị Thùy, Nguyễn Thị Hoàng Anh, Dương Thị Phượng, Phạm Thị Tuyết Nhung, Hà Vân Oanh, Dương Thị Ly Hương, Nguyễn Hữu Tùng, Thành phần saponin của thân rễ sâm vũ diệp thu hái ở Sa Pa, Lào Cai, Tạp chí Dược liệu. 23(2) (2018) 82-88.[6] Wen-zhi Yang, Ying Hu, Wan-ying Wu, Min Ye, De-an Guo, Saponins in the genus Panax L. (Araliaceae): A systematic review of their chemical diversity, Phytochemistry. 106 (2014) 7-14. [7] Shashi B. Mahato, Asish P. Kundu, 13C NMR spectra of pentacyclic triterpenoids - a complication and some salient features, Phytochemistry. 37 (1994) 1517-1575. [8] Pawan K. Agrawal, NMR spectroscopy in the structural elucidation of oligossacharides and glycosides, Phytochemistry. 31 (1992) 1307-1330. [9] Chun Liang, Yan Ding, Huu Tung Nguyen, Jeong-Ah Kim, Hye-Jin Boo, Hee-Kyoung Kang, Mahn Cuong Nguyen, Young Ho Kim, Oleanane –type triterpenoids from Panax stipuleannatus and their anticancer activities, Bioorg Med Chem Lett. 20 (2010) 7110-7115.
APA, Harvard, Vancouver, ISO, and other styles

Dissertations / Theses on the topic "Zhi yao ye"

1

Gu, Donghui. "Shanghai xia gang zhi gong yan jiu she hui zhi chi xi tong, ge ren hui ying yu zai jiu ye = A study of the unemployed in Shanghai : social support systems, individual responses & reemployment /." online access from Digital dissertation consortium, 2000. http://libweb.cityu.edu.hk/cgi-bin/er/db/ddcdiss.pl?9984698.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Zhang, Zhuan. "Xin wen zhuan ye zhu yi zai Zhongguo : "xin wen tiao cha" ge an yan an = Professionalism at work : the case of "New Probe" /." click here to view the abstract and table of contents, 2003. http://net3.hkbu.edu.hk/~libres/cgi-bin/thesisab.pl?pdf=b17563379a.pdf.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Ma, Fengzhi. "Zhongguo cheng shi xia gang shi ye pin kun fu nü qiu zhu he shou zhu jing yan de xu shu fen xi." online access from Digital Dissertation Consortium access full-text, 2006. http://libweb.cityu.edu.hk/cgi-bin/er/db/ddcdiss.pl?3241049.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Ming, Kay-chuen. "The development and decline of modern Chinese private enterprise a case study of the Shanghai textile industry, 1895-1937 = Zhongguo jin dai min ban qi ye zhi fa zhan yu shuai luo : 1895-1937 Shanghai mian fang zhi gong ye ge an yan jiu /." Click to view the E-thesis via HKUTO, 1985. http://sunzi.lib.hku.hk/hkuto/record/B31948650.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Chen, Minzhen. "Meiguo tu shu guan xue hui yu Yingguo tu shu guan xue hui dui tu shu guan shi ye fa zhan zhi bi jiao yan jiu." Taibei Shi ; Niuyue : Han mei tu shu you xian gong si, 1990. http://books.google.com/books?id=6LTSAAAAMAAJ.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Chow, Ka-kin Kelvin. "A study of the social status of the Canadian Chinese during the mid-twentieth century 20 shi ji zhong ye Jianada hua ren di wei zhuan bian zhi yan jiu /." Click to view the E-thesis via HKUTO, 2008. http://sunzi.lib.hku.hk/hkuto/record/B4163374X.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Chow, Ping-wa Timothy. "A study of the educational activities of the Society of Jesus in Hong Kong : with special reference to the Kowloon Wah Yan College = Yesu hui zai Xianggang de jiao yu shi ye yan jiu: yi Jiulong hua ren shu yuan wei zhong xin /." View the Table of Contents & Abstract, 2005. http://sunzi.lib.hku.hk/hkuto/record/B31636640.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Li, Wanhong. "Jiao yu fen quan yu zhi ye jiao yu fa zhan Zhongguo Shanghai, ji Shenzhen fa zhan jing yan de bi jiao yan jiu = Decentralization in education and the development of vocational education : a comparative study on the developmental experience of Shenzhen and Shanghai in China /." online access from Digital dissertation consortium, 2002. http://libweb.cityu.edu.hk/cgi-bin/er/db/ddcdiss.pl?3066595.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Zhi yao ye"

1

Foshan Shi yi yao zong gong si. Foshan Shi yao ye zhi. [Canton: Foshan Shi yi yao zong gong si, 1992.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Qi du yao ye zhi bian zuan wei yuan hui. Qi du yao ye zhi. [Zibo Shi: Shandong qi du yao ye you xian gong si], 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Yan, Jiaming, and Guorong Lü. Ren pin bi neng li geng zhong yao. Bei jing: Dian zi gong ye chu ban she, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Beijing zhi: Gong ye juan : Yi yao gong ye zhi, Yin shua gong ye zhi. Beijing: Beijing chu ban she, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Yang, Elian. Zhi ye jiao yu gai yao. [Beijing: Beijing zhong xian tuo fang ke ji fa zhan you xian gong si, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

bian, Zhang Xiumei Zhu, ed. Yao xue zhuan ye zhi shi. 7th ed. Beijing: Zhong guo yi yao ke ji chu ban she, 2017.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Fujian Sheng Fuzhou yao cai cai gou gong ying zhan. Fuzhou zhong yao shang ye zhi. [Fuzhou: Fujian Sheng Fuzhou yao cai cai gou gong ying zhan, 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Hebei Sheng yi yao gong si. Hebei Sheng yi yao shang ye zhi. [Hebei Sheng: Hebei Sheng yi yao gong si], 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Guang yao ji tuan Qi ye wen hua jian she wei yuan hui. Guang yao gu shi: Chuan qi si bai nian,Ai xin man ren jian : Lü se guang yao. Guang zhou: Guang dong lü you chu ban she, 2016.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

yi, Chen Zongqi, ed. Nu ren yao xiang shou gong zuo, bu yao ren ming gong zuo: Climbing the Ladder in Stilettos : 10 Strategies for Stepping Up to Success and Satisfaction at Work. Tai bei shi: Chun guang chu ban she, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources
You might also be interested in the extended bibliographies on the topic 'Zhi yao ye' for particular source types:
Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography